pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Imaavy
drug
save

nipocalimab

pre_registrationupdated 3mo ago
by $JNJ JOHNSON & JOHNSON
community read0 votes

indications

indications
Lupus

all catalysts(0)

nothing on the calendar yet

Trials studying nipocalimab

  • phase1A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Womenrecruitingn=8
  • phase3Nipocalimab in Moderate to Severe Sjogren's Diseaseactive not recruitingn=655
  • phase3Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravisrecruitingn=115
  • phase3A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosusrecruitingn=600
  • phase3A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravisrecruitingn=199
  • phase3A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)recruitingn=120
  • phase3A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)recruitingn=50
  • phase2A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathiesactive not recruitingn=36
more trials →

News(2)

  • Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
    Plus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic review.”…
    endpoints · 2mo ago
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
    biopharma_dive · 2mo ago
brand
Imaavy
generic
nipocalimab-aahu
indication
Acquired (Autoimmune) Hemolytic Anemia
phase
pre_registration
Data sources
ClinicalTrials.gov
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?